A. Shah

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

M. Reding, T. Coyle, J. Powell, 2014, Journal of thrombosis and haemostasis : JTH.

BAY 94‐9027, a PEGylated recombinant factor VIII, exhibits a prolonged half‐life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies

S. Lalezari, H. Delesen, T. Coyle, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

S. Garger, S. Lalezari, H. Delesen, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81‐8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

R. Ljung, M. Mancuso, G. Kenet, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

B. Ploeger, S. Mcleay, Anita Shah, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.

M. Wainberg, H. von Briesen, H. Rübsamen-Waigmann, 1999, Antiviral research.